Monitor for additional tranche draws under the $8.4M facility, which would further dilute common shareholders. The company's cash burn rate and Nasdaq listing compliance are key watchpoints given the micro-cap market cap.
Price Chart
Executive Summary
Valion Bio drew $250,000 from its existing Securities Purchase Agreement with 3i, LP, issuing 250 Series B Convertible Preferred Shares at $1,000 each and a warrant for 156,026 common shares at $0.61628 per share. This is a routine tranche under a previously disclosed $8.4M facility, but the dilution is material relative to the company's $2M market cap.
Key Financial Metrics
Key Facts
- Issued 250 Series B Non-Voting Convertible Preferred Shares at $1,000 per share to 3i, LP on June 17, 2026
- Issued a warrant to purchase 156,026 shares of common stock at $0.61628 per share
- Aggregate purchase price of $250,000 under the existing Purchase Agreement
- Total facility size is up to $8,400,000; this is a tranche draw
- Securities issued under Section 4(a)(2) and/or Rule 506(b) exemption
Financial Impact
$250,000 capital raise with potential dilution from warrant exercise of 156,026 shares; conversion terms of preferred shares not disclosed
Risk Factors
- Continued dilution from future tranche draws and warrant exercise
- Cash burn may require further capital raises or restructuring
- Potential Nasdaq delisting risk if share price falls below minimum bid requirement
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-004956 |
| Document: 0001683168-26-004956-index-headers.html | 0001683168-26-004956 |
| Document: 0001683168-26-004956-index.html | 0001683168-26-004956 |
| Document: 0001683168-26-004956.txt | 0001683168-26-004956 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.15 | awaiting T+20 | — | $0.8400 (−26.70%) |
Oct 22, 2026 4d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.8400 (−12.13%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8400 (+25.00%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8400 (+25.00%) |
Oct 16, 2026 10d ago | S-3 | $1.16 | awaiting T+20 | — | $0.8400 (+27.59%) |
Oct 16, 2026 10d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.8400 (+27.59%) |
Oct 15, 2026 11d ago | 8-K | $1.23 | awaiting T+20 | — | $0.8400 (−31.71%) |
Oct 14, 2026 12d ago | 8-K | $1.45 | awaiting T+20 | — | $0.8400 (−42.07%) |
Oct 8, 2026 18d ago | 8-K | $2.21 | awaiting T+20 | — | $0.8400 (+61.99%) |
Oct 7, 2026 19d ago | S-3 | $2.21 | awaiting T+20 | — | $0.8400 (+61.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers